Phase 2 Poor Risk DLBCL of TLI and ATG Followed by Matched Allogeneic HT as Consolidation to Autologous HCT

Exclusion Criteria

• •Known allergy to etoposide or a history of Grade 3 hemorrhagic cystitis with cyclophosphamide
• •Greater than Grade 2 sensory or motor peripheral neuropathy from prior vinca alkaloid use
• •Requiring therapy for coronary artery disease, cardiomyopathy, dysrhythmia, or congestive heart failure
• •Known to be human immunodeficiency virus (HIV)-positive. The antibody test for HIV must be performed within 42 days of registration.
• •Prior chemotherapy other than corticosteroids administered within 2 weeks of the initiation of protocol therapy.
• •Prior malignancy, except adequately treated basal cell or squamous cell skin cancer, in situ cervical cancer or other cancer for which the patients has been disease-free for five years.
• •Prior diagnosis of non-Hodgkin's lymphoma
• •Active infection requiring oral or intravenous antibiotics
• •Prior autologous or allogeneic hematopoietic cell transplantation
• •Prior radioimmunotherapy
• •Pregnant
• •Lactating
• •DONOR ELIGIBILITY
• •Related or unrelated HLA-identical donors who are in good health and have no contra-indication to donation
• •No contra-indication for the donor to collection by apheresis of mononuclear cells mobilized by G-CSF at a dose of 16 µg/kg of body weight.
• •Donors will be evaluated with a full history and physical examination.
• •Virology testing including HIV; cytomegalovirus (CMV); Epstein-Barr virus (EBV); human T-lymphotropic virus (HTLV); rapid plasma reagin (RPR); Hepatitis A, B and C be performed within 30 days of donation.
• •Prospective donors will be screened for CMV seroreactivity and seronegative donors will be utilized if available.
• •If more than one human leukocyte antigen (HLA)-matched related donor exists, then the donor will be selected on the basis of CD31 allotype.